Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240765 | 0.82 | FYN (0.49) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL14507283 | 0.82 | FYN (0.54) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL8240040 | 0.81 | FYN (0.51) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL8239679 | 0.81 | FYN (0.47) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL5618445 | 0.81 | FLT3 (0.52) | TTKADORA3AURKAIKBKBFLT3 | |
| SCHEMBL8239774 | 0.80 | FYN (0.47) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL8241565 | 0.80 | MAPKAPK5 (0.48) | FYNEGFRTTKADORA3AURKA | |
| SCHEMBL8246197 | 0.79 | FYN (0.48) | FYNKDM1AEGFRTTKABCG2 | |
| SCHEMBL8241033 | 0.79 | FYN (0.55) | FYNEGFRTTKABCG2ADORA3 | |
| SCHEMBL8239628 | 0.78 | FYN (0.49) | FYNKDM1AEGFRTTKABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | FYN 1691/4885KDM1A 1008/4885EGFR 723/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | FYN 2520/4885KDM1A 1136/4885EGFR 1732/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | FYN 1797/4885KDM1A 446/4885EGFR 1414/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | FYN 655/4885KDM1A 701/4885EGFR 604/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | FYN 334/4885KDM1A 788/4885EGFR 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.